首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1643889

全球乾化學分析儀市場 - 2025-2033

Global Dry Chemistry Analyzer Market - 2025-2033

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 227 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球乾化學分析儀市場規模達177.6億美元，預計2033年將達到286.6億美元，2025-2033年預測期間複合年成長率為4.2%。

乾化學分析儀是一種無需使用液體試劑即可分析樣品的機器，但在分析前會經過與樣品混合的預先測量的試劑包。然而，這在臨床實驗室中很常見。它測試患者的重要參數，如血糖、膽固醇和肝功能。乾化學分析儀會非常準確；然而，在某些情況下，由於使用者的錯誤或樣本品質差，確實會產生錯誤的結果。這需要對實驗室工作人員進行適當的培訓並定期校準。

市場動態：

驅動程式和限制

對即時 (POC) 診斷的需求不斷增加

由於對即時診斷 (POC) 診斷的需求不斷成長，全球乾化學分析儀市場正在成長。 POC 診斷可以在患者護理場所附近進行快速、準確的測試，從而減少對集中實驗室的需求並縮短週轉時間。這對於緊急護理、遠距醫療機構和門診診所尤其有益。乾化學分析儀可攜帶、易於使用且高效，使其成為 POC 應用的理想選擇。糖尿病和心血管疾病等慢性疾病的增加推動了 POC 診斷的採用，而全球向個人化醫療保健的轉變鞏固了它們在現代 POC 診斷解決方案中的作用。

例如，Fujifilm Dri-Chemistry 分析儀在診斷測試領域處於領先地位，具有易用性、準確性和便利性。這些分析儀無需校準，可在簡單的即插即用設定上運行，並且結構緊湊，適合任何醫療保健環境。它們還需要最少的培訓，非常適合遠端和資源有限的環境。

敏感性和特異性有限

由於靈敏度和特異性有限，乾化學分析儀在全球市場面臨挑戰。儘管它們方便且週轉時間短，但與濕化學系統相比，它們在檢測低濃度分析物和處理複雜的診斷測試方面不太穩健。這限制了它們在專業臨床實驗室和需要高精度的先進診斷程序中的應用。這可能會導致診斷不準確，降低臨床醫生的信心並阻礙在高風險醫療環境中的採用。市場現在面臨創新和提高乾化學系統分析能力的壓力，以滿足這些需求。

有關此報告的更多詳細資訊 - 索取樣本

F. Hoffmann-La Roche Ltd.
Siemens Healthineers
Abbott Laboratories
Beckman Coulter, Inc. (A subsidiary of Danaher Corporation)
Ortho Clinical Diagnostics
Sysmex Corporation
Thermo Fisher Scientific, Inc
Randox Laboratories Ltd
Wondfo
Similar data will be provided for each market player.
堀場有限公司
- 管道產品說明
- 產品關鍵績效指標 (KPI)
- 主要活動
- 市場進入時間表
- 產品滲透率
- 銷售估算與預測
愛科來公司
優瑞特醫療電子有限公司
迪瑞實業有限公司
麥迪卡公司
EKF診斷
將為每個市場參與者提供類似的資料。

第 12 章：附錄

簡介目錄

Product Code: MD9059

The global dry chemistry analyzer market reached US$ 17.76 billion in 2024 and is expected to reach US$ 28.66 billion by 2033, growing at a CAGR of 4.2% during the forecast period 2025-2033.

A dry chemistry analyser is a machine that can analyse samples without using liquid reagents, but goes through pre-measured reagent packets that mix with the sample before analysis. This is, however, common in a clinical laboratory; where it tests important parameters in a patient such as blood glucose, cholesterol, and liver function. Dry chemistry analyzers would be very accurate; however, a few occasions do produce false results due to mistakes by users or due to a poor sample quality. This calls for proper training of laboratory staff and regular calibration.

Market Dynamics: Drivers & Restraints

Increasing Demand for Point-of-care (POC) Diagnostics

The global dry chemistry analyzer market is growing due to the growing demand for point-of-care (POC) diagnostics. POC diagnostics enable quick, accurate testing near patient care sites, reducing the need for centralized labs and turnaround times. This is particularly beneficial in emergency care, remote healthcare settings, and outpatient clinics. Dry chemistry analyzers are portable, easy to use, and efficient, making them ideal for POC applications. The rise in chronic diseases like diabetes and cardiovascular conditions has fueled the adoption of POC diagnostics, and the global shift towards personalized healthcare has solidified their role in modern POC diagnostic solutions.

For instance, Fujifilm Dri-Chemistry Analyzers are leading the charge in diagnostic testing, offering ease of use, accuracy, and convenience. These analyzers require no calibration, operate on a simple plug-and-play setup, and are compact enough for any healthcare setting. They also require minimal training and are ideal for remote and resource-limited environments.

Limited Sensitivity and Specificity

Dry chemistry analyzers face challenges in the global market due to their limited sensitivity and specificity. Despite their convenience and quick turnaround time, they are less robust in detecting low-concentration analytes and handling complex diagnostic tests compared to wet chemistry systems. This restricts their application in specialized clinical laboratories and advanced diagnostic procedures that require high precision. This can lead to diagnostic inaccuracies, reducing clinician confidence and hindering adoption in high-stakes medical environments. The market is now pressured to innovate and improve dry chemistry systems' analytical capabilities to meet these demands.

For more details on this report - Request for Sample

Segment Analysis

The global dry chemistry analyzer market is segmented based on product type, technology, application, end user and region.

Product Type:

Instruments segment is expected to dominate the Dry Chemistry Analyzer market share

The instruments segment holds a major portion of the dry chemistry analyzer market share and is expected to continue to hold a significant portion of the dry chemistry analyzer market share during the forecast period.

Instruments play a crucial role in the global dry chemistry analyzer market, as they are diagnostic tools for rapid and accurate testing of biological samples. They are used to diagnose and monitor medical conditions like diabetes, kidney disorders, and liver diseases. Modern instruments' compactness and user-friendliness have increased their adoption in point-of-care settings, outpatient clinics, and rural healthcare facilities.

The DRI-CHEM from FUJIFILM is a dry chemistry analyzer capable of performing multiple clinical chemistry test parameters. It features an auto-pipetting system, requires no calibration, and requires no water, making preparation and maintenance easy. The DRI-CHEM NX500 offers "Real Time and Borderless" Clinical Chemistry.

End User:-

Diagnostic Laboratories segment is the fastest-growing segment in Dry Chemistry Analyzer market share

The diagnostic laboratories segment is the fastest-growing segment in the dry chemistry analyzer market share and is expected to hold the market share over the forecast period.

Diagnostic laboratories are key users of dry chemistry analyzers for various diagnostic applications, including metabolic disorders, liver function, kidney function, and cardiovascular diseases. These analyzers offer accurate, quick, and reliable results, making them ideal for high-throughput environments. They process multiple samples simultaneously, reducing reagent usage and contamination risk. The ease of use, automation, and minimal maintenance requirements of dry chemistry analyzers support laboratories in meeting increasing demand for diagnostic testing.

For instance, in July 2024, Beckman Coulter Diagnostics has introduced the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer. This innovative solution addresses the needs of healthcare systems worldwide, offering solutions for satellite or independent laboratories and core laboratories. Utilizing Beckman Coulter's scalable clinical chemistry and immunoassay portfolio, the DxC 500i Analyzer enables commutable patient results, providing strategic benefits in patient care and inventory management for hospitals and healthcare networks.

Geographical Analysis

North America is expected to hold a significant position in the Dry Chemistry Analyzer market share

North America holds a substantial position in the dry chemistry analyzer market and is expected to hold most of the market share due to its product launches, significant advancements, high adoption of diagnostic technologies. Moreover, the rising prevalence of chronic diseases like diabetes, cardiovascular disorders, and kidney ailments has increased demand for reliable diagnostic solutions. The region's focus on point-of-care testing, substantial healthcare funding, and favorable reimbursement policies have accelerated the adoption of dry chemistry analyzers. Leading market players and ongoing R&D activities further drive innovation.

For instance, in April 2024, he URIT UC-1800 Urine Analyzer has passed the U.S. FDA approval, marking its success as part of the URIT US-2000 series artificial intelligence. This dry chemical analysis module has a single measuring speed of up to 480T/H, making it suitable for high-end markets. It also offers charts and traceable results, with a maximum of 500 test strips in a single run, constant temperature reaction, and easy operation. The UC-1800 provides stable and reliable test results.

Asia Pacific is growing at the fastest pace in the Dry Chemistry Analyzer market

Asia Pacific holds the fastest pace in the dry chemistry analyzer market and is expected to hold most of the market share due to rise in chronic diseases and the need for affordable diagnostic solutions. The aging population and improved healthcare infrastructure in countries like China, India, and Japan are driving the demand for cost-effective diagnostic tools. Government initiatives and the adoption of point-of-care testing in rural areas are also contributing to the market's robust growth.

For instance, chronic diseases are prevalent among older adults in China, with advanced socioeconomic status having a dual-edged impact on their prevalence. The Chinese population has a high prevalence of chronic diseases, with a national prevalence of 81.1%, affecting 179.9 Billion older adults. The prevalence increases with aging and peaking at 80-84 years old. Women, rural residents, and ethnic minorities have a higher prevalence than men, urban residents, and Han ethnicity.

Hence, due to the high prevalence of chronic diseases among older adults, which necessitates rapid, cost-effective, and user-friendly diagnostic tools, especially for underserved populations like rural residents and ethnic minorities which indeed helps the overall growth of the market.

Competitive Landscape

The major global players in the dry chemistry analyzer market include FUJIFILM India Private Limited, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Inc. (A subsidiary of Danaher Corporation), Ortho Clinical Diagnostics, Sysmex Corporation, Thermo Fisher Scientific, Inc, Randox Laboratories Ltd, Wondfo and among others.

Key Developments

In Febraury 2024, Beckman Coulter Diagnostics unveiled its new DxC 500 AU Chemistry Analyzer at Medlab Middle East in Dubai on February 5-8, 2024. This automated clinical chemistry analyzer is part of a series of solutions designed to enhance the capabilities of satellite and independent hospital laboratories, complementing central hub laboratories.
In July 2023, Siemens Healthineers Atellica has received FDA clearance for its 1 in vitro diagnostic for immunoassay and clinical chemistry testing. The analyzer offers competitive advantages for labs with low to medium testing volumes, including improved turnaround time predictability, advanced reporting functionality, and safety and security measures.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global dry chemistry analyzer market report delivers a detailed analysis with 75+ key tables, more than 65 visually impactful figures, and 227 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Demand for Point-of-care (POC) Diagnostics
- 4.1.2. Restraints
  - 4.1.2.1. Limited Sensitivity and Specificity
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Instruments*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Consumables

7. By Technology

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
7.2. Reflectance Photometry*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Colorimetry
7.4. Turbidimetry
7.5. Fluorescence

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Blood Chemistry Analysis*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Urinalysis
8.4. Metabolic Panel Testing
8.5. Liver and Renal Function Testing
8.6. Electrolyte Analysis

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Diagnostic Laboratories*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospitals
9.4. Ambulatory Care Centers
9.5. Academic and Research Institutes
9.6. Point-of-Care Testing Facilities

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

12.1. FUJIFILM India Private Limited*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
  - 12.1.2.1. Product Description
  - 12.1.2.2. Product Key Performance Indicators (KPIs)
  - 12.1.2.3. Historic and Forecasted Product Sales
  - 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
  - 12.1.3.1. Company Revenue's
  - 12.1.3.2. Geographical Revenue Shares
  - 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
  - 12.1.4.1. Mergers & Acquisitions
  - 12.1.4.2. Key Product Development Activities
  - 12.1.4.3. Regulatory Approvals etc.
- 12.1.5. SWOT Analysis
12.2. F. Hoffmann-La Roche Ltd.
12.3. Siemens Healthineers
12.4. Abbott Laboratories
12.5. Beckman Coulter, Inc. (A subsidiary of Danaher Corporation)
12.6. Ortho Clinical Diagnostics
12.7. Sysmex Corporation
12.8. Thermo Fisher Scientific, Inc
12.9. Randox Laboratories Ltd
12.10. Wondfo
Similar data will be provided for each market player.

Emerging Market Players

12.11. HORIBA, Ltd*
- 12.11.1. Pipeline Products Description
- 12.11.2. Product Key Performance Indicators (KPIs)
- 12.11.3. Key Activities
- 12.11.4. Market Entry Timelines
- 12.11.5. Product Penetration Rate
- 12.11.6. Sales Estimation and Projections
12.12. Arkray, Inc.
12.13. URIT Medical Electronic Co., Ltd.
12.14. DIRUI Industrial Co., Ltd.
12.15. Medica Corporation
12.16. EKF Diagnostics
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE